H.C. Wainwright initiated coverage of Virax Biolabs (VRAX) with a Buy rating and $3 price target Virax is a UK-based development-stage in vitro diagnostics company focused on T cell diagnostics, the analyst tells investors in a research note. The firm says that in the U.S., Virax is slated to meet with the FDA in mid-2025 to define the approval pathway and potentially initiate a U.S.-based clinical validation study in the second half of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRAX:
- Virax Biolabs Launches Clinical Study on T Cell Dysfunction
- Virax Biolabs enrolls first patients in T-cell dysfunction study
- Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes
- Virax Biolabs to Present at World Immune Regulation Meeting
- Virax Biolabs Aligns with US Health Department on Vaccine Transparency